Last reviewed · How we verify
AMG102
AMG102 is a recombinant human tumor necrosis factor (TNF) receptor fusion protein.
AMG102 is a recombinant human tumor necrosis factor (TNF) receptor fusion protein. Used for Metastatic colorectal cancer.
At a glance
| Generic name | AMG102 |
|---|---|
| Also known as | Rilotumumab |
| Sponsor | UNICANCER |
| Drug class | TNF-alpha inhibitor |
| Target | TNF-alpha |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
It acts as a decoy receptor for TNF-alpha, thereby inhibiting the interaction between TNF-alpha and its natural receptors, which are involved in the inflammatory response and tumor growth.
Approved indications
- Metastatic colorectal cancer
Common side effects
- Fatigue
- Headache
- Nausea
Key clinical trials
- QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer (PHASE1, PHASE2)
- Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC) (PHASE1, PHASE2)
- Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
- MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma (PHASE2)
- Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches (PHASE2, PHASE3)
- Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (PHASE2)
- AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer (PHASE1, PHASE2)
- A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AMG102 CI brief — competitive landscape report
- AMG102 updates RSS · CI watch RSS
- UNICANCER portfolio CI